The US Food and Drug Administration (FDA) recently advocated psilocybin therapy as a ‘breakthrough therapy’ for the treatment of major depressive disorder (MDD), which the new Jamaican facility also specialises in. The new centre will also be studying the effectiveness of psilocybin (commonly known as magic mushrooms) as a new therapy for opioid addiction, Alzheimer’s disease, post-traumatic stress disorder (PTSD), and anorexia nervosa.
Dr Winston De La Haye, Medical Director of the Aion International Center for Psychedelic Psychiatry, commented: “We need all available and effective products for the treatment of patients with mental illness. Psychedelic Psychiatry has the potential to change the lives of millions of patients, reducing their disability and improving their quality of life.
“As a Johns Hopkins Alumnus, it is our intention to follow the best treatment protocols like those being established at Johns Hopkins Center for Psychedelic and Consciousness Research.”
International expansion on the cards
Dr Stephen Barnhill, Executive Chairman of Aion Therapeutic, added: “We’re very excited to be opening the first International Center for Psychedelic Psychiatry in Jamaica. The Center is unique in our ability to treat patients with both psilocybin and medical cannabis combination therapies currently being produced at Aion Therapeutic in conjunction with our licensed medical cannabis partner Apollon Therapeutics Jamaica, Ltd. We are establishing treatment protocols and dosing schedules for international expansion and export when and where the legal use of these products continues to expand globally.
“We are honoured to have Dr Winston De La Haye, with his significant expertise in addiction medicine as the Medical Director for the treatment facility.”